Model predicts death due to acetaminophen overdose

Model predicts death due to acetaminophen overdose
Model for Acetaminophen-induced Liver Damage, a mathematical model that utilizes commonly obtained laboratory values, including overdose amount and time elapsed since overdose, is effective for predicting outcomes in patients with acute liver failure due to acetaminophen overdose, according to research published online Feb. 13 in Hepatology.

(HealthDay) -- Model for Acetaminophen-induced Liver Damage (MALD), a mathematical model that utilizes commonly obtained laboratory values, including overdose amount and time elapsed since overdose, is effective for predicting outcomes in patients with acute liver failure due to acetaminophen overdose, according to research published online Feb. 13 in Hepatology.

Christopher H. Remien, of the University of Utah in Salt Lake City, and colleagues developed MALD to describe acute due to an overdose of acetaminophen. The model utilizes laboratory values that are commonly obtained on admission, specifically aspartate aminotransferase (AST), alanine aminotransferase (ALT), and international normalized ratio (INR), to estimate the overdose amount, time elapsed, and outcome. The model was tested on 53 patients.

The researchers found that, using only initial ALT, AST, and INR measurements, the model was able to accurately predict follow-up laboratory values for most patients. With the addition of , the researchers were able to predict eventual death due to acetaminophen overdose with 100 percent sensitivity, 91 percent specificity, 67 percent , and 100 percent negative predictive value.

"Our dynamic model yields a prediction of outcome by estimating the time since overdose and overdose amount from commonly obtained laboratory data on admission," the authors write. "Our initial analysis suggests that MALD compares favorably to statistical methods, and should be validated in multicentric retrospective and prospective evaluation."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Better labeling could help thwart acetaminophen overdose

May 03, 2011

While well known for relieving everyday aches and pains, few realize that when misused, acetaminophen can lead to acute liver failure and even death, often due to accidental overdose by an uninformed consumer. A new small ...

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments